Compounds > bucindolol
Page last updated: 2024-08-23

bucindolol and Heart Failure, Systolic

bucindolol has been researched along with Heart Failure, Systolic in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aban, IB; Ahmed, A; Anker, SD; Aronow, WS; Caldentey, G; Deedwania, P; Fletcher, RD; Fonarow, GC; Kheirbek, R; Lo, A; Patel, K; White, M1
Aban, I; Adamopoulos, C; Ahmed, A; Aronow, WS; Banach, M; Deedwania, P; Desai, RV; Feller, MA; Iskandrian, AE; Lainscak, M; Meyer, P; Mujib, M; White, M1
Aban, IB; Ahmed, A; Ahmed, MI; Aronow, WS; Bogaard, HJ; Deedwania, P; Desai, RV; Feller, MA; Fonarow, GC; Guichard, JL; Iskandrian, AE; Meyer, P; Mujib, M; Waagstein, F; White, M1
Aban, IB; Ahmed, A; Ahmed, MI; de Denus, S; Desai, RV; Feller, MA; Guichard, JL; Mujib, M; White, M1

Trials

4 trial(s) available for bucindolol and Heart Failure, Systolic

ArticleYear
Racial differences in mortality in patients with advanced systolic heart failure: potential role of right ventricular ejection fraction.
    International journal of cardiology, 2014, Nov-15, Volume: 177, Issue:1

    Topics: Adrenergic beta-Antagonists; Female; Heart Failure, Systolic; Humans; Incidence; Male; Middle Aged; Propanolamines; Racial Groups; Severity of Illness Index; Stroke Volume; Survival Rate; United States; Ventricular Function, Right

2014
Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients.
    International journal of cardiology, 2012, Feb-23, Volume: 155, Issue:1

    Topics: Age Factors; Aged; Female; Heart Failure, Systolic; Hospitalization; Humans; Male; Predictive Value of Tests; Propanolamines; Stroke Volume; Ventricular Function, Right

2012
Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving β-blockers: insights from the BEST trial.
    International journal of cardiology, 2013, Feb-10, Volume: 163, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Chronic Disease; Female; Heart Failure, Systolic; Humans; Male; Middle Aged; Propanolamines; Stroke Volume; Treatment Outcome; Ventricular Function, Right

2013
Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST.
    The Canadian journal of cardiology, 2012, Volume: 28, Issue:3

    Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure, Systolic; Hospitalization; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Propanolamines; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke Volume; Survival Rate; Treatment Outcome

2012